IFNG and colorectal cancer: Experimental studies indicate that the combination of AT-II and IFN-γ therapy enhances the colorectal cancer immune-microenvironment by blocking IFN-γ-driven activation of the NF-κB p65/PD-L1 signaling pathway, effectively suppressing tumor progression and lung metastases (Wu et al., 2024[125]).